Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary NeuroMetrix Launches Quell™ Wearable Pain Relief Technology
The Only FDA Cleared Wearable for 24/7 Chronic Pain Relief BOSTON --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced the full commercial launch of Quell , which is now available on the Company's product website at QuellRelief.com and at select physicians' offices.
View HTML
Toggle Summary NeuroMetrix to Exhibit at American Diabetes Association 75th Scientific Sessions
Quell ™ Wearable Pain Relief and DPNCheck ® Neuropathy Test to be Featured WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians better manage chronic
View HTML
Toggle Summary NeuroMetrix Closes $14.7 Million Public Offering
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq:NURO) today reported that it has closed its previously announced underwritten public offering. The Company sold 147,000 units, with each unit consisting of one share of Series B convertible preferred stock and 99 warrants exercisable for
View HTML
Toggle Summary NeuroMetrix Reports Availability of Quell™ Wearable Pain Relief Device at Select Healthcare Providers
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq:NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today reported that it has begun to ship
View HTML
Toggle Summary NeuroMetrix Prices Public Offering of $14.7 Million of Convertible Preferred Stock and Warrants
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq:NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today announced that it has priced an
View HTML
Toggle Summary NeuroMetrix Announces First Shipments of Quell™ Wearable Pain Relief Device
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) reported that it has started shipping Quell wearable pain relief devices out of its production and fulfillment facility in Woburn, MA. The initial shipments are directed to leading doctors and thought leaders in chronic pain.
View HTML
Toggle Summary NeuroMetrix To Start Shipping Quell™ Wearable Pain Relief Device In June
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) reported that it anticipates commercial shipments of the Quell wearable pain relief device will begin in June 2015 . The Company also announced that it has officially started accepting pre-orders for Quell directly on its website
View HTML
Toggle Summary NeuroMetrix Continues Progress to Launch of Quell Wearable Pain Relief with Availability of iOS App
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) reported today the Quell™ app is now available in the Apple app store. Quell is an over-the-counter wearable pain relief device that utilizes proprietary non-invasive neurostimulation technology to provide relief from chronic pain.
View HTML
Toggle Summary NeuroMetrix Reports Q1 2015 Financial Results and Highlights
Diabetes Product Revenue Growth, Preparation for Quell Launch WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), today reported financial and business highlights for the quarter ended March 31, 2015 . The Company operates in two primary markets - wearable
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for 2015 First Quarter Financial Results Conference Call
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2015 first quarter financial results before the opening of the market on April 21, 2015 . The Company will host a conference call at 8:00 a.m., Eastern Time on Tuesday April 21, 2015 to
View HTML